101 related articles for article (PubMed ID: 24568463)
1. Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.
Prajoko YW; Aryandono T
Asian Pac J Cancer Prev; 2014; 15(2):595-8. PubMed ID: 24568463
[TBL] [Abstract][Full Text] [Related]
2. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
4. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
Khokher S; Qureshi MU; Mahmood S; Nagi AH
Asian Pac J Cancer Prev; 2013; 14(5):3223-8. PubMed ID: 23803108
[TBL] [Abstract][Full Text] [Related]
5. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
6. Role of nuclear factor-κB in female breast cancer: a study in Indian patients.
Jana D; Das S; Sarkar DK; Mandal S; Maji A; Mukhopadhyay M
Asian Pac J Cancer Prev; 2012; 13(11):5511-5. PubMed ID: 23317209
[TBL] [Abstract][Full Text] [Related]
7. The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-κb), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients.
Prajoko YW; Aryandono T
Asian Pac J Cancer Prev; 2019 May; 20(5):1511-1518. PubMed ID: 31128056
[TBL] [Abstract][Full Text] [Related]
8. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
[TBL] [Abstract][Full Text] [Related]
10. [Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression].
Liu C; Zhou S; Ke CS; Li NP; Wu RL
Ai Zheng; 2007 Sep; 26(9):929-36. PubMed ID: 17927847
[TBL] [Abstract][Full Text] [Related]
11. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.
Aleskandarany MA; Green AR; Rakha EA; Mohammed RA; Elsheikh SE; Powe DG; Paish EC; Macmillan RD; Chan S; Ahmed SI; Ellis IO
Int J Cancer; 2010 Apr; 126(7):1761-9. PubMed ID: 19711345
[TBL] [Abstract][Full Text] [Related]
12. Expression of β-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel.
Yuan SF; Zhu LJ; Zheng WE; Chen H; Wu LL; Zhang W; Sun HY; Chen WJ
Asian Pac J Cancer Prev; 2012; 13(1):361-5. PubMed ID: 22502701
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
14. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.
Jones LW; Fels DR; West M; Allen JD; Broadwater G; Barry WT; Wilke LG; Masko E; Douglas PS; Dash RC; Povsic TJ; Peppercorn J; Marcom PK; Blackwell KL; Kimmick G; Turkington TG; Dewhirst MW
Cancer Prev Res (Phila); 2013 Sep; 6(9):925-37. PubMed ID: 23842792
[TBL] [Abstract][Full Text] [Related]
15. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.
Chung HC; Rha SY; Kim JH; Roh JK; Min JS; Lee KS; Kim BS; Lee KB
Breast Cancer Res Treat; 1997 Jan; 42(1):65-72. PubMed ID: 9116319
[TBL] [Abstract][Full Text] [Related]
17. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
19. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
20. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
